Bariatric surgery: Unstressing or boosting the β-cell?

Diabetes, Obesity and Metabolism

Volumn 11, Issue SUPPL. 4, 2009, Pages 130-142

  Mingrone, G ^a   Castagneto, M ^b  

^a CATHOLIC UNIVERSITY   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

Author keywords

Bariatric surgery; Incretins; Insulin secretion; Insulin sensitivity

Indexed keywords

INCRETIN;

ARTICLE; BARIATRIC SURGERY; BILIOPANCREATIC BYPASS; CLINICAL TRIAL; DISEASE ASSOCIATION; DISEASE SEVERITY; GASTRIC BANDING; GASTROPLASTY; HORMONE RELEASE; HUMAN; HYPERINSULINEMIA; HYPOGLYCEMIA; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; INSULINOMA; JEJUNOILEAL BYPASS; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PANCREAS ISLET BETA CELL; QUALITY OF LIFE; ROUX Y ANASTOMOSIS; STOMACH BYPASS; SURGICAL TECHNIQUE; WEIGHT REDUCTION;

BARIATRIC SURGERY; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; EUROPE; HUMANS; INSULIN-SECRETING CELLS; NESIDIOBLASTOSIS; OBESITY, MORBID; TIME; UNITED STATES;

EID: 70350280194     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2009.01120.x     Document Type: Article

References (70)

1. Ogden CL, Yanovski SZ, Carroll MD, Flegal KM. The epidemiology of obesity. Gastroenterology 2007, 132:2087-2102.
2. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004, 27:1047-1053.
3. Müller-Riemenschneider F, Reinhold T, Berghöjer A, Willich SW. Health-economic burden of obesity in Europe. Eur J Epidemiol 2008, 23:499-509.
4. Cowie CC, Rust KF, Byrd-Holt DD. Prevalence of diabetes and impaired fasting glucose in adults in the U.S. population: National Health And Nutrition Examination Survey 1999-2002. Diabetes Care 2006, 29:1263-1268.
5. Lindström J, Ilanne-Parikka P, Peltonen M. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study. Lancet 2006, 368:1673-1679.
6. Riste L, Khan F, Cruickshank K. High prevalence of type 2 diabetes in all ethnic groups, including Europeans, in a British inner city: relative poverty, history, inactivity, or 21st century Europe?. Diabetes Care 2001, 24:1377-1383.
7. Buchwald H, Avidor Y, Braunwald E. Bariatric surgery: a systematic review and meta-analysis. JAMA 2004, 292:1724-1737.
8. Santry HP, Gillen DL, Lauderdale DS. Trends in Bariatric Surgical Procedures. JAMA 2005, 294:1909-1917.
9. Sjostrom L, Narbro K, Sjostrom CD. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med 2007, 357:741-752.
10. Karlsson J, Taft C, Ryden A, Sjostrom L, Sullivan M. Ten-year trends in health-related quality of life after surgical and conventional treatment for severe obesity: the SOS intervention study. Int J Obes 2007, 31:1248-1261.
11. Ahmad U, Danowski TS, Nolan S, Stephan T, Sunder JH, Bahl VK. Remissions of diabetes mellitus after weight reduction by jejunoileal bypass. Diabetes Care 1978, 1:158-165.
12. Griffen WO, Bivins BA, Bell RM. The decline and fall of the jejunoileal bypass. Surg Gynecol Obstet 1983, 157:301-308.
13. Pories WJ, Caro JF, Flickinger EG, Meelheim HD, Swanson MS. The control of diabetes mellitus (NIDDM) in the morbidly obese with the Greenville Gastric Bypass. Ann Surg 1987, 206:316-323.
14. Mingrone G, DeGaetano A, Greco AV. Reversibility of insulin resistance in obese diabetic patients: role of plasma lipids. Diabetologia 1997, 40:599-605.
15. Guidone C, Manco M, Valera-Mora E. Mechanisms of recovery from type 2 diabetes after malabsorptive bariatric surgery. Diabetes 2006, 55:2025-2031.
16. Sjöström L, Lindroos AK, Peltonen M. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med 2004, 351:2683-2693. Swedish Obese Subjects Study Scientific Group.
17. Mingrone G, Henriksen FL, Greco AV. Triglyceride-induced diabetes associated with familial lipoprotein lipase deficiency. Diabetes 1999, 48:1258-1263.
18. Naslund E, Hellstrom PM, Kral JG. The gut and food intake: an update for surgeons. J Gastrointest Surg 2001, 5:556-567.
19. Welch I, Saunders K, Read NW. Effect of ileal and intravenous infusions of fat emulsions on feeding and satiety in human volunteers. Gastroenterology 1985, 89:1293-1297.
20. Wadden TA, Sternberg JA, Letizia KA, Stunkard AJ, Foster GD. Treatment of obesity by very low calorie diet, behavior therapy, and their combination: a five-year perspective. Int J Obes 1989, 13:39-46.
21. MacDonald KG. Overview of the epidemiology of obesity and the early history of procedures to remedy morbid obesity. Arch Surg 2003, 138:357-360.
22. Jacobs-van der Bruggen MA, Bos G, Bemelmans WJ, Hoogenveen RT, Vijgen SM, Baan CA. Lifestyle interventions are cost-effective in people with different levels of diabetes risk: results from a modeling study. Diabetes Care 2007, 30:128-134.
23. Dixon JB, O'Brien PE, Playfair J. Adjustable gastric banding and conventional therapy for type 2 diabetes: a randomized controlled trial. JAMA 2008, 299:316-323.
24. Pories WJ. Bariatric surgery: risks and rewards. J Clin Endocrinol Metab 2008, 93(Suppl. 1):S89-S96.
25. Pereira JA, Claro BM, Pareja JC. Restored insulin inhibition on insulin secretion in nondiabetic severely obese patients after weight loss induced by bariatric surgery. Int J Obes Relat Metab Disord 2003, 27:463-468.
26. Rodieux F, Giusti V, D'Alessio DA, Suter M, Tappy L. Effects of gastric bypass and gastric banding on glucose kinetics and gut hormone release. Obesity 2008, 16:298-305.
27. Bikman BT, Zheng D, Pories WJ. Mechanism for improved insulin sensitivity after gastric bypass surgery. J Clin Endocrinol Metab 2008, 93:4656-4663.
28. Laferrère B, Teixeira J, McGinty J. Effect of weight loss by gastric bypass surgery versus hypocaloric diet on glucose and incretin levels in patients with type 2 diabetes. J Clin Endocrinol Metab 2008, 93:2479-2485.
29. Patti ME, McMahon G, Mun EC. Severe hypoglycaemia post-gastric bypass requiring partial pancreatectomy: evidence for inappropriate insulin secretion and pancreatic islet hyperplasia. Diabetologia 2005, 48:2236-2240.
30. Rubino F. Is type 2 diabetes an operable intestinal disease? A provocative yet reasonable hypothesis. Diabetes Care 2008, 31:S290-S296.
31. Laferrère B, Heshka S, Wang K. Incretin levels and effect are markedly enhanced 1 month after Roux-en-Y gastric bypass surgery in obese patients with type 2 diabetes. Diabetes Care 2007, 30:1709-1716.
32. le Roux CW, Aylwin SJ, Batterham RL. Gut hormone profiles following bariatric surgery favor an anorectic state, facilitate weight loss, and improve metabolic parameters. Ann Surg 2006, 243:108-114.
33. Hansen BF, Jensen P, Nepper-Christensen E, Skj ølstrup B. Effects of glucagon-like peptide-1 (7-36)amide on insulin stimulated rat skeletal muscle glucose transport. Acta Diabetol 1998, 35:101-103.
34. Adami GF, Cordera R, Camerini G, Marinari GM, Scopinaro N. Recovery of insulin sensitivity in obese patients at short term after biliopancreatic diversion. J Surg Res 2003, 113:217-221.
35. Scopinaro N, Marinari GM, Camerini GB, Papadia FS, Adami GF. Specific effects of biliopancreatic diversion on the major components of metabolic syndrome: a long-term follow-up study. Diabetes Care 2005, 28:2406-2411.
36. Muscelli E, Mingrone G, Camastra S. Differential effect of weight loss on insulin resistance in surgically treated obese patients. Am J Med 2005, 118:51-57.
37. Chiellini C, Rubino F, Castagneto M, Nanni G, Mingrone G. The effect of bilio-pancreatic diversion on type 2 diabetes in patients with BMI < 35 kg/m2. Diabetologia 2009, 52:1027-1030.
38. Salinari S, Bertuzzi A, Asnaghi S, Guidone C, Manco M, Mingrone G. First-phase insulin secretion restoration and differential response to glucose load depending on the route of administration in type 2 diabetic subjects after bariatric surgery. Diabetes Care 2009, 32:375-380.
39. Shneider BL, Dawson PA, Christie DM, Hardikar W, Wong MH, Suchy FJ. Cloning and molecular characterization of the ontogeny of a rat ileal sodium-dependent bile acid transporter. J Clin Invest 1995, 95:745-754.
40. Dawson PA, Haywood J, Craddock AL. Targeted deletion of the ileal bile acid transporter eliminates enterohepatic cycling of bile acids in mice. J Biol Chem 2003, 278:33920-33927.
41. Manfredini G, Ermini M, Scopsi L, Bonaguidi F, Ferrannini E. Internal biliary diversion improves glucose tolerance in the rat. Am J Physiol 1985, 249:G519-G527.
42. Ermini M, Iaconis E, Mori A. The effects of bilio-jejunal diversion on streptozotocin diabetes in the rat. Acta Diabetol Lat 1991, 28:79-89.
43. Rudnicki M, Patel DG, McFadden DW, Balasubramaniam A, Nussbaum MS, Fischer JE. Proximal jejunal and biliary effects on the enteroinsular axis. Surgery 1990, 107:455-460.
44. Holmberg JT, Ihse I, Lundquist I, Ahren B. Influence of bile duct occlusion on plasma insulin responses to glucose in rats. Scand J Gastroenterol 1986, 21:59-64.
45. Garg A, Grundy SM. Cholestyramine therapy for dyslipidemia in non-insulin-dependent diabetes mellitus. A short-term, double-blind, crossover trial. Ann Intern Med 1994, 121:416-422.
46. Dussault I, Beard R, Lin M. Identification of gene-selective modulators of the bile acid receptor FXR. J Biol Chem 2003, 278:7027-7033.
47. Downes M, Verdecia MA, Roecker AJ. A chemical, genetic, and structural analysis of the nuclear bile acid receptor FXR. Mol Cell 2003, 11:1079-1092.
48. Duran-Sandoval D, Mautino G, Martin G. Glucose regulates the expression of the farnesoid X receptor in liver. Diabetes 2004, 53:890-898.
49. Shen H, Zhang Y, Ding H. Farnesoid X receptor induces GLUT4 expression through FXR response element in the GLUT4 promoter. Cell Physiol Biochem 2008, 22:1-14.
50. Letiexhe MR, Scheen AJ, Gérard PL, Desaive C, Lef èbvre PJ. Insulin secretion, clearance and action before and after gastroplasty in severely obese subjects. Int J Obes Relat Metab Disord 1994, 18:295-300.
51. Moxley RT, Lockwood DH, Amatruda JM, Tobin JD, Pozefsky T. Loss of insulin response to ingested amino acids after jejunoileal bypass surgery for morbid obesity. Diabetes 1978, 27:78-84.
52. Service GJ, Thompson GB, Service FJ, Andrews JC, Collazo-Clavell ML, Lloyd RV. Hyperinsulinemic hypoglycemia with nesidioblastosis after gastric-bypass surgery. N Engl J Med 2005, 353:249-254.
53. Cummings DE. Gastric bypass and nesidioblastosis-too much of a good thing for islets?. N Engl J Med 2005, 353:300-302.
54. Sempoux C, Guiot Y, Jaubert F, Rahier J. Focal and diffuse forms of congenital hyperinsulinism: the keys for differential diagnosis. Endocr Pathol 2004, 15:241-246.
55. Wasada T. Adenosine triphosphate-sensitive potassium (K(ATP)) channel activity is coupled with insulin resistance in obesity and type 2 diabetes mellitus. Intern Med 2002, 41:84-90.
56. Meier JJ, Butler AE, Galasso R, Butler PC. Hyperinsulinemic hypoglycemia after gastric bypass surgery is not accompanied by islet hyperplasia or increased beta-cell turnover. Diabetes Care 2006, 29:1554-1559.
57. Roth DA, Meade RC. Hyperinsulinism-hypoglycemia in the postgastrectomy patient. Diabetes 1965, 14:526-528.
58. Cameron AJ, Ellis JP, Mcgill JT, Lequesne LP. Insulin response to carbohydrate ingestion after gastric surgery with special reference to hypoglycemia. Gut 1969, 10:825-830.
59. Leichter SB, Arnold AC, Lewis SB. Glucose tolerance, insulin secretion, and glucose utilization in subjects after gastric surgery. Am J Clin Nutr 1977, 30:2053-2060.
60. Takemura J, Seino Y, Yamamura T. The role of endogenous gastric inhibitory polypeptide in the enteroinsular axis. J Clin Endocrinol Metab 1982, 54:909-913.
61. Andreasen JJ, Orskov C, Holst JJ. Secretion of glucagon-like peptide-1 and reactive hypoglycemia after partial gastrectomy. Digestion 1994, 55:221-228.
62. Polyzogopoulou EV, Kalfarentzos F, Vagenakis AG, Alexandrides TK. Restoration of euglycemia and normal acute insulin response to glucose in obese subjects with type 2 diabetes following bariatric surgery. Diabetes 2003, 52:1098-1103.
63. Porte D, Kahn SE. Beta-cell dysfunction and failure in type 2 diabetes: potential mechanisms. Diabetes 2001, 50(Suppl. 1):S160-S163.
64. Briatore L, Salani B, Andraghetti G. Restoration of acute insulin response in T2DM subjects 1 month after biliopancreatic diversion. Obesity 2008, 16:77-81.
65. Kotronen A, Juurinen L, Tiikkainen M, Vehkavaara S, Yki-Järvinen H. Increased liver fat, impaired insulin clearance, and hepatic and adipose tissue insulin resistance in type 2 diabetes. Gastroenterology 2008, 135:122-130.
66. Festa A, Williams K, D'Agostino R, Wagenknecht LE, Haffner SM. The natural course of beta-cell function in nondiabetic and diabetic individuals: the Insulin Resistance Atherosclerosis Study. Diabetes 2006, 55:1114-1120.
67. Mingrone G, Nolfe G, Castagneto Gissey G. Circadian rhythms of GIP and GLP1 in glucose-tolerant and in type 2 diabetic patients after biliopancreatic diversion. Diabetologia 2009, 52:872-881.
68. McClean PL, Irwin N, Hunter K, Gault VA, Flatt PR. (Pro(3))GIP[mPEG]: novel, long-acting, mPEGylated antagonist of gastric inhibitory polypeptide for obesity-diabetes (diabesity) therapy. Br J Pharmacol 2008, 155:690-701.
69. Miyawaki K, Yamada Y, Ban N. Inhibition of gastric inhibitory polypeptide signaling prevents obesity. Nat Med 2002, 8:738-742.
70. Irwin N, McClean PL, Patterson S, Hunter K, Flatt PR. Active immunisation against gastric inhibitory polypeptide (GIP) improves blood glucose control in an animal model of obesity-diabetes. Biol Chem 2009, 390:75-80.